Recent News

• 08.12.2025 - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.12.2025 - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 06.27.2025 - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
• 06.27.2025 - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
• 06.02.2025 - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
• 06.02.2025 - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Recent Filings

• 08.01.2025 - 8-K Current report
• 07.31.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 07.30.2025 - EFFECT Notice of Effectiveness
• 07.22.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 07.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.10.2025 - 144 Report of proposed sale of securities
• 06.27.2025 - 8-K Current report
• 06.27.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.27.2025 - EX-99.1 EX-99.1